Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 3

2(28.6%)

Phase 2

1(14.3%)

7Total

Phase 1(4)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06388083Phase 2Active Not Recruiting

A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease

Role: lead

NCT05949593Phase 3Active Not Recruiting

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy

Role: lead

NCT05244304Phase 3Completed

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease

Role: lead

NCT05266014Phase 1Completed

This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease

Role: collaborator

NCT05667688Phase 1Completed

Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Aged 50-85

Role: collaborator

NCT04005807Phase 1Completed

Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults

Role: lead

NCT03735810Phase 1Completed

Safety and Tolerability Study of LBS-008 in Healthy Adult Subjects After Single and Multiple Doses

Role: collaborator

All 7 trials loaded